|Expense ratio (net)||N/A|
|Last cap gain||N/A|
|Morningstar risk rating||N/A|
|Beta (5Y monthly)||N/A|
|5y average return||N/A|
|Average for category||N/A|
The TV host said last week that investors should avoid Pfizer. He should listen to his own previous advice about this big pharma stock.
The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.
Investing.com – Stocks fell sharply Monday afternoon and money poured into bonds again as worries about global trade battles grew.
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
Pfizer's proposed deal with Mylan is complicated. But if you're a Pfizer shareholder, here's what you need to know.